Neuroendocrine, autonomic, and metabolic responses to an orexin antagonist, suvorexant, in psychiatric patients with Insomnia

Innovations in Clinical Neuroscience

Volumn 14, Issue 3-4, 2017, Pages 30-37

  Nakamura, Masaru ^a   Nagamine, Takahiko ^b  

^a Kosekai Kusatsu Hospital   (Japan)

^b Sunlight Brain Research Center   (Japan)

Author keywords

Autonomic nervous; Insomnia; Neuroendocrine; Orexin antagonist; Psychiatry; Suvorexant

Indexed keywords

HYDROCORTISONE; INSULIN; NORADRENALIN; PROLACTIN; SUVOREXANT;

ADULT; ALCOHOL PSYCHOSIS; ANXIETY; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; DEPRESSION; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSOMNIA; JAPAN; LEUKOCYTE COUNT; MALE; METABOLIC DISORDER; METABOLOMICS; MIDDLE AGED; MOOD DISORDER; NEUROENDOCRINE SYSTEM; PATIENT HEALTH QUESTIONNAIRE 9; PITTSBURGH SLEEP QUALITY INDEX; PROSPECTIVE STUDY; PULSE RATE; SCHIZOPHRENIA; SCORING SYSTEM; SLEEP; SLEEP DISORDER; SLEEP TIME;

EID: 85019691825     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bernardis LL, Bellinger LL. The lateral hypothalamic area revisited: ingestive behavior. Neurosci Biobehav Rev. 1996;20:189-287.
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-585.
3. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322-327.
4. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015.
5. Nambu T, Sakurai T, Mizukami K, et al. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999;827:243-260.
6. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;537:1257-1263.
7. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A. 1999;96:748-753.
8. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron. 2003;38:701-713.
9. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437-451.
10. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469-474.
11. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345-354.
12. Hirota K, Kushikata T, Kudo M, et al. Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats. Brain Res. 2003;981:143-150.
13. Kayaba Y, Nakamura A, Kasuya Y, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol. 2003;285:R581-593.
14. Al-Barazanji KA, Wilson S, Baker J, et al. Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. J Neuroendocrinol. 2001;13:421-424.
15. Brunton PJ, Russell JA.?Hypothalamic-pituitary-adrenal responses to centrally administered orexin-A are suppressed in pregnant rats. J Neuroendocrinol. 2003;15:633-637.
16. Hagan JJ, Leslie RA, Patel S, et al.?Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 1999;96:10911-10916.
17. Smart D, Haynes AC, Williams G, Arch JR. Orexins and the treatment of obesity. Eur J Pharmacol. 2002;440:199-212.
18. United States Food and Drug Administration FDA News Release: FDA Approves New Type of Sleep Drug. Belsomra. 2014. [Accessed March 17, 2015]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm.
19. Parker T. Merck enters the Insomnia market through the launch of Belsomra in Japan. 2014. [Accessed May 12, 2015]. GlobalData Website. Available from: http://healthcare.globaldata.com/resources/expert-insights/pharmaceuticals/merck-enters-the-insomnia-market-through-the-launch-of-belsomra-in-japan.
20. World Health Organization site. International Statistical Classification of Diseases and Related Health Problems 10th Revision. http://apps.who.int/classifications/icd10/browse/2016/en. Accessed 30 April 2017.
21. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
22. Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.
23. Spitzer RL, Kroenke K, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
24. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry. 2016;79:136-148. doi: 10.1016/j.biopsych.2014.10.003.
25. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461-471. doi: 10.1016/S1474-4422(14)70053-5.
26. Russell SH, Kim MS, Small CJ, et al. Central administration of orexin A suppresses basal and domperidone stimulated plasma prolactin. J Neuroendocrinol. 2000;12:1213-1218.
27. Samson WK, Bagley SL, Ferguson AV, White MM. Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress. Am J Physiol Regul Integr Comp Physiol. 2007;292:R382-387.
28. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523-1631.
29. Chang YS, Chen HL, Wu YH, et al. Rotating night shifts too quickly may cause anxiety and decreased attentional performance, and impact prolactin levels during the subsequent day: a case control study. BMC Psychiatry. 2014;14:218. doi: 10.1186/s12888-014-0218-7.
30. Schwartz MW, Seeley RJ, Tschöp MH, et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature. 2013;503:59-66. doi: 10.1038/nature12709.
31. Funato H. Orexin and metabolism. In: Sakurai T, Pandi-Perumal SR, Monti JM (eds). Orexin and Sleep: Molecular, Functional and Clinical Aspects. New York:?Springer; 2015:363-390.
32. Kalsbeek A, Yi CX, la Fleur SE, et al. Suprachiasmatic nucleus and autonomic nervous system influences on awakening from sleep. Int Rev Neurobiol. 2010;93:91-107.
33. Tsuneki H, Wada T, Sasaoka T. Role of orexin in the central regulation of glucose and energy homeostasis. Endocr J. 2012;59:365-374.
34. Shiuchi T, Haque MS, Okamoto S, et al. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab. 2009;10:466-480. doi: 10.1016/j.cmet.2009.09.013.
35. Perez-Leighton CE, Billington CJ, Kotz CM. Orexin modulation of adipose tissue. Biochim Biophys Acta. 2014;1842:440-445.
36. Tsuneki H, Tokai E, Nakamura Y, et al. Hypothalamic orexin prevents hepatic insulin resistance via daily bidirectional regulation of autonomic nervous system in mice. Diabetes. 2015;64:459-470. doi: 10.2337/db14-0695.
37. Haynes AC, Chapman H, Taylor C, et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept. 2002;104:153-159.
38. Shirasaka T, Nakazato M, Matsukura S, et al. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277:R1780-1785.
39. Li A, Hindmarch CC, Nattie EE, Paton JF. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591:4237-4248. doi: 10.1113/jphysiol.2013.256271.
40. Kuru M, Ueta Y, Serino R, et al. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport. 2000;11:1977-1980.
41. Lu J, Bjorkum AA, Xu M, et al. Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep. J Neurosci. 2002;22:4568-4576.
42. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6-25.
43. Malendowicz LK, Hochol A, Ziolkowska A, et al. Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland. Int J Mol Med. 2001;7:401-404.
44. Spinazzi R, Rucinski M, Neri G, et al. Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells. J Clin Endocrinol Metab. 2005;90:3544-3549.
45. Kok SW, Roelfsema F, Overeem S, et al. Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. J Clin Endocrinol Metab. 2002;87:5085-5091.
46. Nakagawa M, Terashima T, D’yachkova Y, et al. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation. 1998;98:2307-2313.
47. Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M. Catecholamine-induced leukocytosis: early observations, current research, and future directions. Brain Behav Immun. 1996;10:77-91.
48. Patel AX, Miller SR, Nathan PJ, et al. Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans. Psychopharmacology (Berl). 2014;231:3817-3828. doi: 10.1007/s00213-014-3520-7